Idexx Laboratories IDXX Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 247.1%+0.8pp | 246.3%+0.8pp | 245.6%+1.0pp | 244.6%+1.1pp | 243.4%+1.1pp | |
| Operating margin | 125.7%+2.5pp | 123.2%+2.7pp | 120.5%+2.4pp | 118.1%+2.5pp | 115.6%-0.8pp | |
| Net margin | 98.3%+1.9pp | 96.4%+1.8pp | 94.6%+2.1pp | 92.5%+2.1pp | 90.4%-0.5pp | |
| EBITDA margin | 139.1%+2.4pp | 136.7%+2.7pp | 134%+2.5pp | 131.5%+2.7pp | 128.9%-0.5pp | |
| Free cash flow margin | 91.5%+2.8pp | 88.7%+3.8pp | 84.8%+2.5pp | 82.3%-2.7pp | 85.1%+0.2pp | |
| Returns | ||||||
| Return on equity | 268.6%+13.6pp | 255%+8.5pp | 246.5%+5.2pp | 241.3%+1.6pp | 239.7%-12.6pp | |
| Return on assets | 124.8%+5.9pp | 118.9%+4.8pp | 114.1%+3.6pp | 110.5%+2.3pp | 108.2%-0.9pp | |
| Return on invested capital | 213.5%+11.4pp | 202%+7.4pp | 194.7%+6.8pp | 187.9%+6.2pp | 181.7%-3.8pp | |
| Efficiency | ||||||
| Asset turnover | 5.1×+0.2× | 4.9×+0.1× | 4.8×0.0× | 4.8×0.0× | 4.8×0.0× | |
| Inventory turnover | 16.8×+0.5× | 16.3×+0.3× | 16×+0.2× | 15.7×+0.2× | 15.6×+0.1× | |
| Liquidity | ||||||
| Current ratio | 4.6×0.0× | 4.7×-0.1× | 4.8×-0.2× | 5×-0.3× | 5.3×-0.4× | |
| Quick ratio | 3.4×0.0× | 3.4×-0.1× | 3.4×-0.2× | 3.6×-0.2× | 3.8×-0.4× | |
| Cash ratio | 0.6×0.0× | 0.6×-0.1× | 0.7×-0.1× | 0.9×-0.2× | 1.1×-0.3× | |
| Leverage | ||||||
| Debt-to-equity | 1.6×-0.1× | 1.7×-0.1× | 1.8×0.0× | 1.9×-0.1× | 2×0.0× | |
| Debt-to-assets | 0.7×-0.1× | 0.8×-0.1× | 0.8×0.0× | 0.9×0.0× | 0.9×0.0× | |
| Net debt / EBITDA | 1.2×-0.2× | 1.4×-0.1× | 1.5×0.0× | 1.5×0.0× | 1.5×+0.1× | |
| Interest coverage | 143×-0.9× | 143.9×-1.2× | 145.1×+1.4× | 143.6×+4.8× | 138.8×+6.3× | |
| Per Share | ||||||
| Book value per share | $76.59+2.3% | $74.85+0.9% | $74.20-0.2% | $74.33-1.2% | $75.27-1.3% | |
| Valuation | ||||||
| Market capitalization | $192.43B+5.8% | $181.83B+12.5% | $161.66B+6.2% | $152.3B+1.5% | $150.12B-6.7% | |
| Enterprise value | $194.14B+5.7% | $183.75B+12.3% | $163.63B+6.1% | $154.25B+1.5% | $152B-6.6% | |
| Price / earnings | 184.8×+2.7× | 182.1×+12.9× | 169.2×+1.6× | 167.6×-4.6× | 172.2×-13.7× | |
| Price / sales | 45.4×+1.4× | 44×+3.9× | 40.2×+1.4× | 38.8×-0.1× | 38.9×-3.4× | |
| Price / book | 124.3×+5.2× | 119.1×+12.4× | 106.7×+6.9× | 99.8×+3.6× | 96.1×-5.1× | |
| EV / EBITDA | 131.7×+1.9× | 129.8×+8.9× | 120.9×+1.6× | 119.4×-3.0× | 122.3×-9.7× | |
| EV / sales | 45.8×+1.3× | 44.5×+3.8× | 40.7×+1.4× | 39.3×-0.1× | 39.4×-3.4× | |
| Free cash flow yield | 8.1%-0.1pp | 8.2%-0.4pp | 8.6%0.0pp | 8.6%-0.2pp | 8.8%+0.7pp | |
| Earnings yield | 8.7%-0.2pp | 8.9%-0.7pp | 9.6%-0.1pp | 9.6%+0.2pp | 9.4%+0.7pp | |
| PEG ratio | 9.7×-9.8× | 19.5×-4.9× | 24.4×-6.4× | 30.9×-4.4× | 35.2×+9.4× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Idexx Laboratories's profit margins?
- Idexx Laboratories (IDXX) runs a 62.1% gross margin and a 31.6% operating margin, with a 24.6% net margin.
- Where do Idexx Laboratories's ratios come from?
- Every ratio is computed from Idexx Laboratories's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
